secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000920148-24-000115
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10
--------------------------------------------------------------------------------

- Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.
- FY 2024 adj EPS midpoint lowered $0.10 to $14.30-$14.70 on ~$0.15 weather hit; FCF $161.5M.
- Diagnostics revenue $2.55B (+8.9% YoY), base business organic 5.7%; Biopharma rev $737.7M (+2.6%).
- Announced acquisitions of Ballad Health outreach assets, Lab Works, and Naples lab mgmt; closed Invitae and BioReference Health purchases.
- Quarterly dividend $0.72/share declared, payable Dec 13, 2024 to holders of record Nov 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014824000115/0000920148-24-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014824000115/lh-20241024.htm
  HTML page:      https://secwatch.observer/filing/0000920148-24-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer